LPA rs140570886: Healthspan and Cardiovascular Risk
rs140570886 is a single-nucleotide polymorphism located in the human LPA gene on chromosome 6. Genetic studies have identified this variant as an independent contributor to circulating lipoprotein(a) concentrations and cardiovascular risk, influencing overall healthspan and disease-free survival. While carrying the minor allele is associated with increased atherogenic potential, it represents a statistical marker of susceptibility rather than a deterministic diagnosis.
What each genotype means
Typical cardiovascular risk profile
This genotype represents the common, non-risk version of this variant. Research indicates that individuals with this profile do not carry the specific genetic association with elevated lipoprotein(a) levels or increased coronary heart disease risk linked to the minor allele of rs140570886.
This is the most common genotype, found in the vast majority of individuals across global populations.
Increased cardiovascular risk
Carrying one copy of the minor allele (A) is associated with an increased risk of coronary artery disease and has been linked to unexplained familial hypercholesterolemia in some studies. This variant influences risk through both additive genetic effects and complex interactions with other nearby genetic markers in the LPA gene. Please discuss your cardiovascular health and lipid profile with your clinician.
This heterozygous genotype is carried by a small percentage of the population, with a minor allele frequency reported around 0.08 in European populations.
Elevated cardiovascular risk
Individuals with two copies of the minor allele (A) show evidence of increased risk for coronary artery disease compared to those without the variant. This genotype is associated with modulated cardiovascular risk and may contribute to higher lipoprotein(a) levels. It is important to manage overall cardiovascular health factors and discuss your risk profile with a healthcare provider.
This homozygous genotype is rare in the general population.
Variant Characteristics and Genomic Context
The variant rs140570886 is a single-nucleotide variation mapped to the LPA gene region on the short arm of chromosome 6 (6q26–q27). Biochemically, it resides within a non-coding regulatory or intronic framework of the gene rather than directly altering an amino acid sequence. Despite its non-coding nature, the variant lies within an intricately structured genomic neighborhood that governs the expression and structural variation of apolipoprotein(a). Genomic studies often evaluate rs140570886 alongside other hallmark markers at this locus, revealing that non-coding variants can modulate transcription efficiency, post-transcriptional processing, or serve as tightly linked proxies for pathogenic copy number variations. Understanding where rs140570886 sits helps geneticists untangle how localized variations influence long-range gene regulation, ultimately shaping lipid metabolism and circulating cardiovascular biomarkers.
Biological Role of the LPA Gene
The LPA gene encodes apolipoprotein(a), an essential structural component of lipoprotein(a) [Lp(a)]. In the bloodstream, apolipoprotein(a) covalently binds to apolipoprotein B-100 on low-density lipoprotein (LDL)-like particles via a disulfide bond. Lp(a) particles are known for their pro-atherogenic, pro-inflammatory, and potentially pro-thrombotic properties due to structural homology with plasminogen. Plasma levels of Lp(a) are predominantly genetically determined, with 70% to 90% of circulating variation controlled directly by the LPA locus. Much of this variation is historically attributed to the Kringle IV type 2 (KIV-2) copy number repeat polymorphism, where smaller protein isoforms correlate with higher secretion and plasma concentrations. Specific single-nucleotide polymorphisms like rs140570886 act independently or epistatically within this locus, modifying expression patterns and driving inter-individual variability in circulating lipid profiles.
Scientific Research, Healthspan, and Cardiovascular Links
Genome-wide association studies (GWAS) and cohort investigations have linked rs140570886 to cardiovascular phenotypes, premature familial hypercholesterolemia presentations, and healthy aging metrics. Research indicates that the minor risk allele associates with higher Lp(a) levels and accelerated atherosclerotic cardiovascular disease, which directly modulates healthspan—defined as the period of life spent free from chronic, disabling illnesses. Studies exploring cis-epistasis at the LPA locus demonstrate that rs140570886 interacts with neighboring markers to influence disease severity. Evidence strength for this specific variant is categorized as moderate: while the broader causal relationship between elevated Lp(a) and cardiovascular endpoints is robustly verified via Mendelian randomization, the isolated effect size of rs140570886 varies depending on the underlying genomic background and isoform architecture.
Population Distribution and Ancestry Considerations
Allele distributions for rs140570886 exhibit noticeable variation across different global ancestral groups. In populations of European descent, the minor allele frequency is estimated between 0.02 and 0.08, indicating it is an uncommon to low-frequency variant. Comprehensive population databases such as gnomAD show that the frequency of this specific single-nucleotide variant can diverge sharply in African, East Asian, South Asian, and Middle Eastern populations. Furthermore, because the overall LPA locus is subject to complex ancestral architectures—including diverse median Lp(a) baselines and differing KIV-2 repeat frequencies—the clinical penetrance of rs140570886 cannot be assumed uniform across different ethnic backgrounds without considering broader ancestry-specific genetic context.
Translating Genetic Results into Context
Possessing a risk-associated genotype at rs140570886 does not constitute a clinical diagnosis of heart disease, nor does the absence of the variant eliminate cardiovascular risk. Cardiovascular health and human longevity are multifactorial traits shaped by dozens of genetic loci alongside lifestyle, diet, smoking status, and blood pressure control. For consumers reviewing personal genomics data, discovering a risk-associated allele serves primarily as an educational talking point for healthcare consultations. Clinicians frequently evaluate overall cardiovascular health using established blood biomarkers, such as direct clinical serum Lp(a) measurements and standard lipid panels, before contemplating clinical interventions or therapies.
How common is this variant?
The minor risk allele for rs140570886 demonstrates a frequency of roughly 0.02 to 0.08 in European populations according to gnomAD and GWAS cohorts. Frequencies in non-European ancestries remain less characterized or significantly lower, reflecting the complex genetic architecture of the LPA locus.
Frequently asked questions
What does a risk allele at rs140570886 mean for my health?
Carrying a risk allele at rs140570886 indicates a statistical predisposition to higher lipoprotein(a) levels and associated cardiovascular risks. It is not a clinical diagnosis of heart disease. Many carriers maintain normal heart health throughout their lives when other lifestyle and biological risk factors are well managed.
Does having this variant guarantee high lipoprotein(a) levels?
No, it does not guarantee high Lp(a) levels. Although the LPA gene strongly influences Lp(a) production, circulating levels depend heavily on copy number repeats (KIV-2 isoforms) and other co-inherited genetic variants. A standard quantitative blood test is the only reliable way to measure your actual circulating Lp(a) concentration.
How does rs140570886 affect human longevity and healthspan?
Healthspan refers to the length of time an individual remains healthy and free from serious chronic disease. Because cardiovascular events are among the primary causes of disability and mortality in older adults, genetic variants that elevate cardiovascular susceptibility can statistically shorten disease-free survival over a lifetime.
Can diet or lifestyle lower the risk associated with this variant?
Circulating Lp(a) levels themselves are primarily determined by genetics and rarely respond significantly to standard diet or exercise interventions. However, maintaining optimal cardiovascular health through exercise, a balanced diet, blood pressure management, and smoking cessation significantly lowers your overall cardiovascular disease risk regardless of genetics.
Should I change any medications based on my rs140570886 genotype?
You should never change, begin, or discontinue any medications based solely on a raw genetic report. Genotypes merely provide statistical associations, and medical management depends on established clinical laboratory measurements and clinical evaluation by a licensed healthcare provider.
Sources & further reading
Educational information only, last refreshed 9/7/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs140570886?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in LPA
This variant in the LPA gene elevates serum lipoprotein(a) levels, significantly increasing the risk of coronary atherosclerosis and aortic stenosis.
Variant in the LPA gene locus associated with circulating lipoprotein(a) levels and cardiovascular healthspan.
Intronic splice-affecting variant in LPA leading to elevated plasma lipoprotein(a) concentrations and increased risk of aortic valve stenosis and coronary disease.
A splice-altering variant in LPA that lowers circulating lipoprotein(a) levels and is significantly associated with extended parental attained age and healthspan.
Intronic variant in LPA strongly associated with elevated circulating lipoprotein(a) levels and increased risk for coronary artery disease and aortic stenosis.
This variant is strongly associated with significantly elevated levels of Lipoprotein(a), a major independent risk factor for heart disease.